COLL: רווח למניה בשנים עשר החודשים האחרונים Collegium Pharmaceutical Inc

Collegium Pharmaceutical (COLL) profitability relies on patent protection and the sale of non-opioid medications. The trailing 12-month earnings per share trend demonstrates financial stability, where the parameter value equals 0.98. Management efficiency is evident in the successful acquisition of niche drugs, while commitment to ESG principles is reflected in strict distribution control and the eco-friendly disposal of chemical waste during production.

Earnings per share (EPS TTM) measures the ultimate efficiency of the business by allocating total annual income, net of all expenses, per common share. By analyzing the trailing twelve-month earnings per share, an investor assesses the ability of Collegium Pharmaceutical (COLL) to monetize its unique abuse-deterrent drug delivery system, which creates high market barriers for competitors.